InsightfulValue
← Home

Fuji Pharma
Fuji Pharma

-8.33%

Pharma / Pharmaceuticals and medical products manufacturing


πŸ”§ Tools

βœ… Due Diligence
Company at a Glance

Fuji Pharma

πŸ“Š Get full analytics about Fuji Pharma

Sign up for free or log in

πŸ’‘ Learn smarter stock picks with "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

Price
Live  
Overview
Fuji Pharma is a Japanese pharmaceutical company that was founded in 1965. The company specializes in the research, development, production, and sale of pharmaceutical products, with a focus on prescription medicines and OTC drugs. Fuji Pharma’s headquarters are located in Tokyo, Japan.
The company’s main areas of focus include gastroenterology, central nervous system disorders, and dermatology. Fuji Pharma has a strong commitment to research and development, investing a significant portion of its revenue into developing new and innovative medicines.
The company also has a global presence, with subsidiaries and affiliates in countries such as the United States, China, and Thailand. Fuji Pharma’s international operations focus on expanding its business and making its products available in new markets.
In addition to its core pharmaceutical business, Fuji Pharma is also involved in various community initiatives and supports projects related to healthcare and education.
Fuji Pharma’s mission is to contribute to the health and well-being of people worldwide by providing high-quality medicines and healthcare solutions. The company strives to achieve this through its continuous research and development efforts and partnerships with global organizations and healthcare professionals.
How to explain to a 10 year old kid about the company?
Fuji Pharma

πŸ“ˆ Want to read more about Fuji Pharma?

Sign up for free or log in

πŸ†“ Discover "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" β€” free eBook!

RnVqaSBQaG FybWEgaXMg YSBjb21wYW 55IHRoYXQg bWFrZXMgbW VkaWNpbmUg dG8gaGVscC BwZW9wbGUg ZmVlbCBiZX R0ZXIgd2hl biB0aGV5IG FyZSBzaWNr LiBKdXN0IG xpa2UgaG93 IGEgZG9jdG 9yIGdpdmVz IHlvdSBtZW RpY2luZSwg RnVqaSBQaG FybWEgd29y a3MgdG8gY3 JlYXRlIHRo b3NlIG1lZG ljaW5lcyB0 aGF0IGFyZS B1c2VkIGlu IGhvc3BpdG FscyBhbmQg cGhhcm1hY2 llcy48YnI+ VGhlIHdheS BGdWppIFBo YXJtYSBtYW tlcyBtb25l eSBpcyBieS BzZWxsaW5n IGl0cyBtZW RpY2luZXMg dG8gZGlmZm VyZW50IHBs YWNlcywgbG lrZSBob3Nw aXRhbHMgb3 IgZHJ1Z3N0 b3Jlcy4gV2 hlbiBwZW9w bGUgYnV5IG 1lZGljaW5l IGZyb20gdG hvc2UgcGxh Y2VzLCB0aG UgZHJ1Z3N0 b3JlcyBhbm QgaG9zcGl0 YWxzIHBheS BGdWppIFBo YXJtYSBmb3 IgaXQuIFRo ZSBjb21wYW 55IGFsc28g c2VsbHMgaX RzIG1lZGlj aW5lIHRvIG 90aGVyIGNv dW50cmllcy wgd2hpY2gg aGVscHMgdG hlbSBtYWtl IGV2ZW4gbW 9yZSBtb25l eS48YnI+Rn VqaSBQaGFy bWEgaXMgc3 VjY2Vzc2Z1 bCBmb3IgYS BmZXcgcmVh c29ucy4gRm lyc3QsIHRo ZXkgaGF2ZS BzY2llbnRp c3RzIGFuZC ByZXNlYXJj aGVycyB3aG 8gYXJlIHJl YWxseSBnb2 9kIGF0IGNy ZWF0aW5nIG 5ldyBtZWRp Y2luZXMsIG VzcGVjaWFs bHkgZm9yIG hlYXJ0IHBy b2JsZW1zIG FuZCBpbmZl Y3Rpb25zLi BUaGV5IGtl ZXAgaW1wcm 92aW5nIHRo ZWlyIG1lZG ljaW5lcyBh bmQgZmluZG luZyBuZXcg d2F5cyB0by BoZWxwIHBl b3BsZS4gU2 Vjb25kLCBw ZW9wbGUgbm VlZCBtZWRp Y2luZSBhbG wgdGhlIHRp bWUsIHNvIH RoZXJlIGlz IGFsd2F5cy BhIHdheSBm b3IgdGhlIG NvbXBhbnkg dG8gc2VsbC BpdHMgcHJv ZHVjdHMuID xicj5Mb29r aW5nIGludG 8gdGhlIGZ1 dHVyZSwgRn VqaSBQaGFy bWEgaXMgbG lrZWx5IHRv IGNvbnRpbn VlIGJlaW5n IHN1Y2Nlc3 NmdWwgYmVj YXVzZSB0aG VyZSBhcmUg YWx3YXlzIG 5ldyBoZWFs dGggcHJvYm xlbXMgdGhh dCBuZWVkIH RvIGJlIHNv bHZlZCBhbm QgcGVvcGxl IHdpbGwgYW x3YXlzIG5l ZWQgaGVscC B0byBmZWVs IGJldHRlci 4gV2l0aCB0 aGVpciBmb2 N1cyBvbiBp bm5vdmF0aW 9uIGFuZCBo ZWxwaW5nIH Blb3BsZSwg dGhleSBjYW 4ga2VlcCBj b21pbmcgdX Agd2l0aCBu ZXcgbWVkaW NpbmVzIGFu ZCBzdGF5IG ltcG9ydGFu dCBpbiB0aG UgaGVhbHRo Y2FyZSB3b3 JsZC48YnI+
What is special about the company?
Fuji Pharma

πŸ“ˆ Want to read more about Fuji Pharma?

Sign up for free or log in

πŸ“˜ Claim your free eBook: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

MS4gSGlzdG 9yaWNhbCBy b290czogVG hlIEZ1amkg UGhhcm1hIG NvbXBhbnkg aGFzIGEgbG 9uZyBoaXN0 b3J5LCB0cm FjaW5nIGl0 cyByb290cy BiYWNrIHRv IDE5MzQgd2 hlbiBpdCB3 YXMgZXN0YW JsaXNoZWQg YXMgYSBwaG FybWFjZXV0 aWNhbCBjaG VtaWNhbCBj b21wYW55IG luIEphcGFu Ljxicj4yLi BXaWRlIHJh bmdlIG9mIH Byb2R1Y3Rz OiBUaGUgY2 9tcGFueSBo YXMgYSBkaX ZlcnNlIHBv cnRmb2xpby BvZiBwcm9k dWN0cyB0aG F0IGNvdmVy IHZhcmlvdX MgYXJlYXMg b2YgaGVhbH RoY2FyZSBp bmNsdWRpbm cgcGhhcm1h Y2V1dGljYW xzLCBtZWRp Y2FsIGRldm ljZXMsIGRp YWdub3N0aW NzLCBhbmQg ZnVuY3Rpb2 5hbCBmb29k cy48YnI+My 4gRm9jdXMg b24gaW5ub3 ZhdGlvbjog RnVqaSBQaG FybWEgaW52 ZXN0cyBoZW F2aWx5IGlu IHJlc2Vhcm NoIGFuZCBk ZXZlbG9wbW VudCB0byBk ZXZlbG9wIG 5ldyBtZWRp Y2luZXMgYW 5kIHRyZWF0 bWVudHMgZm 9yIHZhcmlv dXMgZGlzZW FzZXMgYW5k IGhlYWx0aC Bjb25kaXRp b25zLjxicj 40LiBRdWFs aXR5IGNvbn Ryb2w6IFRo ZSBjb21wYW 55IGhhcyBz dHJpY3QgcX VhbGl0eSBj b250cm9sIG 1lYXN1cmVz IGluIHBsYW NlIHRvIGVu c3VyZSB0aG Ugc2FmZXR5 IGFuZCBlZm ZlY3RpdmVu ZXNzIG9mIG l0cyBwcm9k dWN0cy48Yn I+NS4gR2xv YmFsIHByZX NlbmNlOiBX aGlsZSB0aG UgY29tcGFu eSBpcyBiYX NlZCBpbiBK YXBhbiwgaX QgaGFzIGEg Z2xvYmFsIH ByZXNlbmNl IHdpdGggb2 ZmaWNlcyBh bmQgc3Vic2 lkaWFyaWVz IGluIHZhcm lvdXMgY291 bnRyaWVzLC BpbmNsdWRp bmcgdGhlIF VuaXRlZCBT dGF0ZXMsIE NoaW5hLCBh bmQgRXVyb3 BlLjxicj42 LiBQYXJ0bm Vyc2hpcHMg YW5kIGNvbG xhYm9yYXRp b25zOiBGdW ppIFBoYXJt YSBoYXMgZX N0YWJsaXNo ZWQgcGFydG 5lcnNoaXBz IGFuZCBjb2 xsYWJvcmF0 aW9ucyB3aX RoIGxlYWRp bmcgcmVzZW FyY2ggaW5z dGl0dXRpb2 5zIGFuZCBw aGFybWFjZX V0aWNhbCBj b21wYW5pZX MsIGFsbG93 aW5nIGZvci B0aGUgZXhj aGFuZ2Ugb2 Yga25vd2xl ZGdlIGFuZC ByZXNvdXJj ZXMgdG8gYW R2YW5jZSBo ZWFsdGhjYX JlLjxicj43 LiBDb21taX RtZW50IHRv IGNvcnBvcm F0ZSBzb2Np YWwgcmVzcG 9uc2liaWxp dHk6IFRoZS Bjb21wYW55 IGFjdGl2ZW x5IHBhcnRp Y2lwYXRlcy BpbiBpbml0 aWF0aXZlcy B0aGF0IGNv bnRyaWJ1dG UgdG8gdGhl IHdlbGwtYm Vpbmcgb2Yg c29jaWV0eS wgaW5jbHVk aW5nIHN1cH BvcnRpbmcg aGVhbHRoY2 FyZSBhY2Nl c3MgaW4gZG V2ZWxvcGlu ZyBjb3VudH JpZXMgYW5k IGVudmlyb2 5tZW50YWwg c3VzdGFpbm FiaWxpdHku PGJyPjguIE VtcGxveWVl IGRldmVsb3 BtZW50OiBG dWppIFBoYX JtYSB2YWx1 ZXMgaXRzIG VtcGxveWVl cyBhbmQgaW 52ZXN0cyBp biB0aGVpci BkZXZlbG9w bWVudCB0aH JvdWdoIHRy YWluaW5nIG FuZCBjYXJl ZXIgZ3Jvd3 RoIG9wcG9y dHVuaXRpZX MuPGJyPjku IFN0cm9uZy BmaW5hbmNp YWwgcGVyZm 9ybWFuY2U6 IFRoZSBjb2 1wYW55IGhh cyBhIHNvbG lkIGZpbmFu Y2lhbCB0cm FjayByZWNv cmQsIGRlbW 9uc3RyYXRp bmcgaXRzIH N0YWJpbGl0 eSBhbmQgc3 VjY2VzcyBp biB0aGUgcG hhcm1hY2V1 dGljYWwgaW 5kdXN0cnku PGJyPjEwLi BDb21taXRt ZW50IHRvIG V0aGljYWwg cHJhY3RpY2 VzOiBGdWpp IFBoYXJtYS Bmb2xsb3dz IGV0aGljYW wgYnVzaW5l c3MgcHJhY3 RpY2VzIGFu ZCBhZGhlcm VzIHRvIHN0 cmljdCBjb2 1wbGlhbmNl IHN0YW5kYX JkcyB0byBw cm9tb3RlIH RyYW5zcGFy ZW5jeSBhbm QgdHJ1c3Qg d2l0aCBzdG FrZWhvbGRl cnMu
What the company's business model?
Fuji Pharma

πŸ“ˆ Want to read more about Fuji Pharma?

Sign up for free or log in

πŸ‘₯ Free eBook for new users: "The Checklist Value Investor β€” A Smarter Way to Pick Stocks"

RnVqaSBQaG FybWEgaXMg YSBKYXBhbm VzZSBwaGFy bWFjZXV0aW NhbCBjb21w YW55IHdpdG ggYSBidXNp bmVzcyBtb2 RlbCBmb2N1 c2VkIG9uIH Jlc2VhcmNo IGFuZCBkZX ZlbG9wbWVu dCwgcHJvZH VjaW5nIGFu ZCBtYXJrZX RpbmcgYnJh bmRlZCBpbm 5vdmF0aXZl IHByZXNjcm lwdGlvbiBk cnVncywgYW 5kIHByb3Zp ZGluZyBtZW RpY2FsIGRl dmljZSBhbm QgaGVhbHRo Y2FyZSBzZX J2aWNlcy4g VGhleSBhbH NvIGhhdmUg YSBzdHJvbm cgZm9jdXMg b24gbGljZW 5zaW5nIGFu ZCBwYXJ0bm Vyc2hpcCBh Z3JlZW1lbn RzIHdpdGgg b3RoZXIgY2 9tcGFuaWVz IHRvIGV4cG FuZCB0aGVp ciBwcm9kdW N0IHBvcnRm b2xpbyBhbm QgZ2xvYmFs IHByZXNlbm NlLiBBZGRp dGlvbmFsbH ksIHRoZSBj b21wYW55IG 1haW50YWlu cyBhIHN0cm 9uZyBlbXBo YXNpcyBvbi BldGhpY2Fs IGFuZCBzb2 NpYWxseSBy ZXNwb25zaW JsZSBwcmFj dGljZXMsIG FzIHdlbGwg YXMgY29udG ludW91cyBp bXByb3ZlbW VudCB0aHJv dWdoIGludm VzdG1lbnQg aW4gdGVjaG 5vbG9neSBh bmQgaHVtYW 4gcmVzb3Vy Y2VzLg==
Is AI a threat?
AI can pose several potential threats to a pharmaceutical company like Fuji Pharma in terms of its products, services, or competitive positioning.
1. Substitution: AI technologies are increasingly capable of developing new drugs and therapies more quickly and effectively than traditional methods. Companies utilizing AI for drug discovery might introduce innovative products that could outperform or substitute Fuji Pharma’s existing offerings. Additionally, AI can enhance preventative and personalized medicine, which could change the market demand for certain pharmaceutical products.
2. Disintermediation: AI and digital health platforms can facilitate more direct interaction between patients and healthcare solutions, potentially bypassing traditional pharmaceutical sales and distribution channels. This could reduce the relevance of established players in the market, including Fuji Pharma, as new business models emerge, and patients prefer direct access to treatments or telehealth solutions.
3. Margin Pressure: As AI enables more efficient drug development and distribution processes, the overall cost of bringing new drugs to market may decrease. This could lead to increased competition and price pressure from both new entrants leveraging AI technology and existing companies improving their efficiency. If Fuji Pharma cannot match the cost structures of its competitors, it may face significant margin pressure.
In summary, while AI can offer opportunities for pharmaceutical innovation and efficiency, it also carries material risks related to substitution, disintermediation, and margin pressure that Fuji Pharma must address to maintain its competitive positioning.
Sensitivity to interest rates
The sensitivity of Fuji Pharma’s earnings, cash flow, and valuation to changes in interest rates can be influenced by several factors:
1. Earnings Sensitivity: Interest rates can impact Fuji Pharma’s profitability through various channels. Higher interest rates may lead to increased borrowing costs if the company has variable-rate debt. This could reduce net income as interest expenses rise. Conversely, lower interest rates can enhance earnings by reducing debt servicing costs. Additionally, interest rate changes can affect the demand for healthcare products and services, particularly if they influence consumer spending or the financial health of healthcare providers.
2. Cash Flow Sensitivity: Cash flow is highly sensitive to interest rates, especially if Fuji Pharma relies on external financing to support its operations or expansion. Higher rates may constrain cash flows due to increased interest payments. Moreover, if the company invests in projects or R&D funded by debt, the cost of capital becomes crucial; higher rates could diminish the attractiveness of such investments, potentially impacting future cash flows.
3. Valuation Sensitivity: The company’s valuation is closely tied to the discount rate used in financial models to determine the present value of future cash flows. When interest rates rise, the discount rate typically increases, which can lead to lower valuations. This is particularly relevant for growth-oriented companies like Fuji Pharma, where much of their value is derived from anticipated future earnings. Conversely, lower interest rates can lead to higher valuations by reducing the discount rate.
Overall, Fuji Pharma’s financial performance and market valuation are affected by interest rate changes, making it essential for the company to monitor economic conditions and adjust its financial strategies accordingly.
Resilience to the future changes
Fuji Pharma

πŸ“ˆ Want to read more about Fuji Pharma?

Sign up for free or log in

πŸ“š Your free copy of "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" is waiting

T25lIHJlYW xpc3RpYyBz Y2VuYXJpby B0aGF0IGNv dWxkIHBlcm 1hbmVudGx5 IGltcGFpci BGdWppIFBo YXJtYeKAmX MgZWNvbm9t aWNzIG92ZX IgdGhlIG5l eHQgM+KAkz UgeWVhcnMg aXMgdGhlIG ludHJvZHVj dGlvbiBvZi BhZ2dyZXNz aXZlIHByaW NlIGNvbnRy b2xzIG9yIH JlZ3VsYXRp b25zIGluIG 1ham9yIHBo YXJtYWNldX RpY2FsIG1h cmtldHMsIH BhcnRpY3Vs YXJseSBpbi BKYXBhbiBh bmQgb3RoZX Iga2V5IHJl Z2lvbnMgd2 hlcmUgdGhl IGNvbXBhbn kgb3BlcmF0 ZXMuIElmIH RoZSBnb3Zl cm5tZW50IG ltcGxlbWVu dHMgc3RyaW 5nZW50IG1l YXN1cmVzIH RvIGNhcCBk cnVnIHByaW NlcywgdGhp cyBjb3VsZC BkcmFtYXRp Y2FsbHkgcm VkdWNlIHRo ZSBwcm9maX RhYmlsaXR5 IG9mIEZ1am kgUGhhcm1h 4oCZcyBwcm 9kdWN0cywg ZXNwZWNpYW xseSBpZiB0 aGUgY29tcG FueSBoYXMg YSBwb3J0Zm 9saW8gdGhh dCByZWxpZX Mgb24gaGln aC1tYXJnaW 4gc3BlY2lh bHR5IGRydW dzLjxicj5J biB0aGlzIH NjZW5hcmlv LCBGdWppIF BoYXJtYeKA mXMgcHJvZm l0IG1hcmdp bnMgY291bG QgZGVjbGlu ZSBzaWduaW ZpY2FudGx5 LiBBcyBwcm ljZSBjb250 cm9scyByZW R1Y2UgdGhl IHJldmVudW UgZ2VuZXJh dGVkIHBlci B1bml0IHNv bGQsIHRoZS Bjb21wYW55 4oCZcyBvcG VyYXRpbmcg bWFyZ2lucy BtYXkgc2hy aW5rLCBsZW FkaW5nIHRv IGRlY3JlYX NlZCBuZXQg aW5jb21lLi BJZiB0aGUg Y29tcGFuee KAmXMgZHJ1 ZyBkZXZlbG 9wbWVudCBw aXBlbGluZS ByZXF1aXJl cyBzdWJzdG FudGlhbCBp bnZlc3RtZW 50LCB0aGUg cmVkdWNlZC BjYXNoIGZs b3cgZnJvbS BvcGVyYXRp b25zIGNvdW xkIGFsc28g aGluZGVyIG l0cyBhYmls aXR5IHRvIG Z1bmQgb25n b2luZyBhbm QgZnV0dXJl IHJlc2Vhcm NoIGFuZCBk ZXZlbG9wbW VudCBwcm9q ZWN0cywgcG 90ZW50aWFs bHkgbGVhZG luZyB0byBh IHNsb3dkb3 duIGluIGlu bm92YXRpb2 4gYW5kIG1h cmtldCBjb2 1wZXRpdGl2 ZW5lc3MuPG JyPkNhc2gg ZmxvdyB3b3 VsZCBiZSBh ZHZlcnNlbH kgYWZmZWN0 ZWQgYXMgd2 VsbC4gV2l0 aCByZWR1Y2 VkIHJldmVu dWVzIGFuZC Bwb3RlbnRp YWwgaW5jcm Vhc2VzIGlu IG9wZXJhdG lvbmFsIGNv c3RzIGR1ZS B0byBtYWlu dGFpbmluZy BSJmFtcDtE IGludmVzdG 1lbnRzLCB0 aGUgY29tcG FueSBtYXkg ZmFjZSB0aW dodGVyIGNh c2ggZmxvdy 4gVGhpcyBz Y2VuYXJpby Bjb3VsZCBh bHNvIGxlYW QgdG8gaW5j cmVhc2VkIG JvcnJvd2lu ZyB0byBmaW 5hbmNlIGRh aWx5IG9wZX JhdGlvbnMg YW5kIFImYW 1wO0QsIGZ1 cnRoZXIgaW 1wYWN0aW5n IGZpbmFuY2 lhbCBzdGFi aWxpdHkuPG JyPlRoZSBi YWxhbmNlIH NoZWV0IGNv dWxkIHJlZm xlY3QgdGhl c2UgY2hhbG xlbmdlcyBh cyB3ZWxsLi BBIGRlY2xp bmUgaW4gcm V0YWluZWQg ZWFybmluZ3 MgZHVlIHRv IGRpbWluaX NoZWQgcHJv Zml0cyB3b3 VsZCByZXN1 bHQgaW4gcm VkdWNlZCBl cXVpdHkuIE FkZGl0aW9u YWxseSwgaW 5jcmVhc2Vk IGxpYWJpbG l0aWVzIGZy b20gYWRkaX Rpb25hbCBk ZWJ0IHRha2 VuIG9uIHRv IG1haW50YW luIG9wZXJh dGlvbnMgY2 91bGQgd29y c2VuIHRoZS BkZWJ0LXRv LWVxdWl0eS ByYXRpbywg c2lnbmFsaW 5nIGhpZ2hl ciBmaW5hbm NpYWwgcmlz ayB0byBpbn Zlc3RvcnMu IE92ZXIgdG ltZSwgdGhp cyBzY2VuYX JpbyBtaWdo dCBsZWFkIH RvIGEgc3Ry YXRlZ2ljIH JldHJlYXQg ZnJvbSBjZX J0YWluIG1h cmtldHMsIG N1dGJhY2tz IGluIFImYW 1wO0Qgc3Bl bmRpbmcsIG FuZCBwb3Rl bnRpYWxseS B3b3JrZm9y Y2UgcmVkdW N0aW9ucywg aW1wYWN0aW 5nIGVtcGxv eWVlIG1vcm FsZSBhbmQg dGFsZW50IH JldGVudGlv bi4gPGJyPk 92ZXJhbGws IHN1Y2ggcm VndWxhdG9y eSBjaGFuZ2 VzIHdvdWxk IGplb3Bhcm RpemUgRnVq aSBQaGFybW HigJlzIGxv bmctdGVybS BlY29ub21p YyB2aWFiaW xpdHkgYW5k IHB1dCBwcm Vzc3VyZSBv biBpdHMgZm luYW5jaWFs IHN0YWJpbG l0eSBhbmQg Z3Jvd3RoIH Byb3NwZWN0 cy48YnI+
Interesting facts about the company
Fuji Pharma

πŸ“ˆ Want to read more about Fuji Pharma?

Sign up for free or log in

πŸš€ Don’t miss "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" β€” free!

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3Mvbn dIZkU1V1Rl aTVnZEVVU2 tvVGMud2Vi cCIgYWx0PS JGdWppIFBo YXJtYSIgdG l0bGU9IkZ1 amkgUGhhcm 1hIiAgY2xh c3M9ImltZy 1mbHVpZCIg aGVpZ2h0PT UwIHdpZHRo PTUwIGxvYW Rpbmc9J2xh enknIHN0eW xlPSdib3Jk ZXItcmFkaX VzOiA2cHg7 Jz4KCiAgIC AgICAgICAg ICAgICAgIC AgPGRpdiBz dHlsZT0nZm xleDogMTsg dGV4dC1hbG lnbjogY2Vu dGVyOyBtYX JnaW4tbGVm dDogNXB4Oy c+CiAgICAg ICAgICAgIC AgICAgICAg ICAgIDxwIH N0eWxlPSdm b250LXNpem U6IDI2cHg7 IGNvbG9yOi AjMzMzOyBt YXJnaW4tYm 90dG9tOiAx NXB4Oyc+Ci AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICDwn5 OIIFdhbnQg dG8gcmVhZC Btb3JlIGFi b3V0IEZ1am kgUGhhcm1h PwogICAgIC AgICAgICAg ICAgICAgIC AgICA8L3A+ CgogICAgIC AgICAgICAg ICAgICAgIC AgICA8YSBo cmVmPSdpbm RleC5waHA/ cGFnZT1zaW dudXAnIHN0 eWxlPScKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGJhY2 tncm91bmQt Y29sb3I6IC MwMDdCRkY7 CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBj b2xvcjogI2 ZmZjsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH ggMjBweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIGJv cmRlci1yYW RpdXM6IDVw eDsKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IHRleHQtZG Vjb3JhdGlv bjogbm9uZT sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG ZvbnQtd2Vp Z2h0OiBib2 xkOwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgbWFyZ2lu LXJpZ2h0Oi AxMHB4Owog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgdHJh bnNpdGlvbj ogYmFja2dy b3VuZC1jb2 xvciAwLjNz IGVhc2U7Jw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgb2 5tb3VzZW92 ZXI9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA1Nm IzIicKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIG9ubW91 c2VvdXQ9J3 RoaXMuc3R5 bGUuYmFja2 dyb3VuZENv bG9yPSIjMD A3QkZGIic+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBT aWduIHVwIG ZvciBmcmVl CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDwvYT4K CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDxzcGFu IHN0eWxlPS dtYXJnaW46 IDAgOHB4Oy Bjb2xvcjog IzU1NTsnPm 9yPC9zcGFu PgoKICAgIC AgICAgICAg ICAgICAgIC AgICAgPGEg aHJlZj0naW 5kZXgucGhw P3BhZ2U9bG 9naW4nIHN0 eWxlPScKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGNvbG 9yOiAjMDA3 QkZGOwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgdGV4dC 1kZWNvcmF0 aW9uOiB1bm RlcmxpbmU7 CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBm b250LXdlaW dodDogNTAw Oyc+CiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICBsb2cgaW 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgPC9hPg oKCiAgICAg ICAgICAgIC AgICAgICAg ICAgIDxwIH N0eWxlPSdt YXJnaW4tdG 9wOiAxNXB4 OyBmb250LX NpemU6IDEz cHg7IGZvbn Qtd2VpZ2h0 OiBib2xkOy Bjb2xvcjog I2QzMmYyZj snPgogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC Ag4pqhIElu c3RhbnRseS BhY2Nlc3Mg PGk+IlRoZS BDaGVja2xp c3QgVmFsdW UgSW52ZXN0 b3Ig4oCUIE EgU21hcnRl ciBXYXkgdG 8gUGljayBT dG9ja3MiPC 9pPiDigJQg ZnJlZSEKIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9wPgoKIC AgICAgICAg ICAgICAgIC AgICAgICAg PCEtLQogIC AgICAgICAg ICAgICAgIC AgICAgICA8 ZGl2IHN0eW xlPSdtYXJn aW4tdG9wOi AxMnB4OyBm b250LXNpem U6IDEzcHg7 IGNvbG9yOi AjNDQ0Oyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBT aWduIHVwIG 5vdyBhbmQg Z2V0IG91ci BmcmVlIGVC b29rIAogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgPGI+VG hlIENoZWNr bGlzdCBWYW x1ZSBJbnZl c3RvciDigJ QgQSBTbWFy dGVyIFdheS B0byBQaWNr IFN0b2Nrcz wvYj4KICAg ICAgICAgIC AgICAgICAg ICAgICAgPC 9kaXY+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC 0tPgogICAg ICAgICAgIC AgICAgICAg ICAgICA8IS 0tCiAgICAg ICAgICAgIC AgICAgICAg ICAgIDxkaX Ygc3R5bGU9 J21hcmdpbi 10b3A6IDE2 cHg7IGZvbn Qtc2l6ZTog MTRweDsgY2 9sb3I6ICM0 NDQ7IGZvbn QtZmFtaWx5 OiAtYXBwbG Utc3lzdGVt LCBCbGlua0 1hY1N5c3Rl bUZvbnQsIF NlZ29lIFVJ LCBSb2JvdG 8sIEhlbHZl dGljYSBOZX VlLCBzYW5z LXNlcmlmOy BsaW5lLWhl aWdodDogMS 42Oyc+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBIYXZl IHlvdSBoZW FyZCBhYm91 dCBvdXIgc2 hvcnQgPHN0 cm9uZyBzdH lsZT0nZm9u dC13ZWlnaH Q6IDYwMDsn PkRhaWx5IF ZpZGVvIE5l d3NsZXR0ZX I8L3N0cm9u Zz4/CiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICA8YSBocm VmPSdodHRw czovL3d3dy 5pbnNpZ2h0 ZnVsdmFsdW UuY29tL25l d3NsZXR0ZX IucGhwJyB0 YXJnZXQ9J1 9ibGFuaycg c3R5bGU9J2 NvbG9yOiAj MDA3QkZGOy B0ZXh0LWRl Y29yYXRpb2 46IG5vbmU7 IGZvbnQtd2 VpZ2h0OiA1 MDA7IG1hcm dpbi1sZWZ0 OiA2cHg7Jz 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBGaW5k IG91dCBtb3 JlCiAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIC A8L2E+CiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvZGl2Pgog ICAgICAgIC AgICAgICAg ICAgICAgIC AtLT4KICAg ICAgICAgIC AgICAgICAg ICA8L2Rpdj 4KICAgICAg ICAgICAgIC AgIDwvZGl2 PgogICAgIC AgICAgICA8 L2Rpdj4KIC AgICAgICAg ICAgCiAgIC AgICAgCiAg ICAgICAgPH NwYW4gY2xh c3M9J2JsdX JyZWQtdGV4 dCc+CiAgIC AgICAgICAg IE1TNGdWR2 hsSUcgTnZi WEJoYm5rZy BkMkZ6SUda dmRXIDVrWl dRZ2FXNGcg TVRrME5pQm hjeSBCT2FX aHZiaUJRIG IzVnNkR2xq WlMgQkRieT RzSUV4MCBa QzRnWW5rZ1 ZHIDl5ZFNC TGFYTm8gYV N3Z1lTQndh RyBGeWJXRm phWE4wIElI ZG9ieUJrWl ggWmxiRzl3 WldRZyBZU0 J3YjNWc2RH IGxqWlNBb1 lTQnogYjJa MExDQnRiMi BsemRDQnRZ WE56IElHOW 1JRzFoZEcg VnlhV0ZzTE NCMCBlWEJw WTJGc2JIIG tnWTI5dWMy bHogZEdsdV p5QnZaaSBC M2FHVmhkQ0 JuIFpYSnRJ Rzl5SUcgOT BhR1Z5SUhO MSBZbk4wWV c1alpYIE1z SUdGd2NHeH AgWldRZ2RH OGdkRyBobE lHSnZaSGtn IGRHOGdjbV ZzYVcgVjJa U0J6YjNKbC BibVZ6Y3lC aGJtIFFnYV c1bWJHRnQg YldGMGFXOX VLUyBCbWIz SWdkSEpsIF lYUnBibWNn WW4gVnlibk 11UEdKeSBQ akl1SUVsdU lEIEU1TlRB c0lIUm8gWl NCamIyMXdZ VyA1NUlHTm 9ZVzVuIFpX UWdhWFJ6SU cgNWhiV1Vn ZEc4ZyBSbl ZxYVNCTlpX IFJwWTJGc0 lFbHUgWkhW emRISnBaWC BNZ1EyOHVM Q0JNIGRHUX VJR0Z1WkMg QmxlSEJoYm 1SbCBaQ0Jw ZEhNZ2NIIE p2WkhWamRD QnMgYVc1bE lIUnZJRyBs dVkyeDFaR1 VnIGJHbHVh VzFsYm4gUn pMQ0J2YVc1 MCBiV1Z1ZE hNc0lHIEZ1 WkNCdmRHaG wgY2lCd2FH RnliVyBGal pYVjBhV05o IGJDQndjbT lrZFcgTjBj eTQ4WW5JKy BNeTRnU1c0 Z2RHIGhsSU RFNU5qQnog TENCR2RXcH BJRSAxbFpH bGpZV3dnIF NXNWtkWE4w Y20gbGxjeU JEYnk0cyBJ RXgwWkM0Z2 JXIFZ5WjJW a0lIZHAgZE dnZ1JuVnFh UyBCWllXdD FhR2x1IElF TnZMaXdnVE ggUmtMaUIw YnlCbSBiM0 p0SUVaMWFt IGtnVUdoaG NtMWggSUVO dkxpd2dUSC BSa0xqeGlj ajQwIExpQk piaUF4T1Qg WTBMQ0IwYU dVZyBZMjl0 Y0dGdWVTIE JzWVhWdVky aGwgWkNCcG RITWdjRyA5 d2RXeGhjaU J3IGNtOWtk V04wSUUgdD ViMnQxYzJW dSBMQ0JoSU hSdmNHIGxq WVd3Z1lXNW wgYzNSb1pY UnBZeSBCbW IzSWdkSEps IFlYUnBibW NnYlggVnpZ MnhsSUhCaC BhVzR1UEdK eVBqIFV1SU VsdUlERTUg Tmpnc0lFWj FhbSBrZ1VH aGhjbTFoIE lHSmxZMkZ0 WlMgQjBhR1 VnWm1seSBj M1FnU21Gd1 lXIDVsYzJV Z2NHaGggY2 0xaFkyVjFk RyBsallXd2 dZMjl0IGNH RnVlU0IwYn kgQnBiblJ5 YjJSMSBZMl VnWVNCemIy IFowSUdOaG NITjEgYkdV Z2JXRnVkVy BaaFkzUjFj bWx1IFp5Qn NhVzVsTGog eGljajQyTG lCSiBiaUF4 T1RjMkxDIE JHZFdwcElG Qm8gWVhKdF lTQmxjMyBS aFlteHBjMm hsIFpDQmhJ SEpsYzIgVm hjbU5vSUdG dSBaQ0JrWl habGJHIDl3 YldWdWRDQm ogWlc1MFpY SWdkRyA4Z1 ptOWpkWE1n IGIyNGdhVz V1YjMgWmhk R2wyWlNCay BjblZuSUdS cGMyIE52ZG 1WeWVTQmgg Ym1RZ1pHVj JaVyB4dmNH MWxiblF1IF BHSnlQamN1 SUUgbHVJRE l3TURNcyBJ RVoxYW1rZ1 VHIGhoY20x aElHRmogY1 hWcGNtVmtJ RyBFZ2JXRn VkV1poIFkz UjFjbWx1Wn kgQm1ZV05w YkdsMCBlU0 JwYmlCVGRY IHBvYjNVc0 lFTm8gYVc1 aExDQmhjeS BCd1lYSjBJ RzltIElHbD BjeUJsZUgg Qmhibk5wYj I0ZyBhVzUw YnlCMGFHIF VnYVc1MFpY SnUgWVhScG IyNWhiQyBC dFlYSnJaWF F1IFBHSnlQ amd1SUUgbH VJREl3TVRF cyBJRVoxYW 1rZ1VHIGho Y20xaElHRm ogY1hWcGNt VmtJRyBFZ0 1UQXdKU0J6 IGRHRnJaU0 JwYmkgQkNZ VzVuYTI5ci BJRUpwYjJ4 dloyIGxqWV d3Z1VISnYg WkhWamRITW dRMiA4dUxD Qk1kR1F1IE xDQmhJRzFo Ym4gVm1ZV0 4wZFhKbCBj aUJ2WmlCd2 FHIEZ5YldG alpYVjAgYV dOaGJDQndj bSA5a2RXTj BjeXdnIGRt RmpZMmx1Wl ggTXNJR0Z1 WkNCdCBaV1 JwWTJGc0lH IFJsZG1sal pYTXMgSUhS dklITjBjbS BWdVozUm9a VzRnIGFYUn pJSEJ5Wlgg TmxibU5sSU dsdSBJSFJv WlNCVGIzIF YwYUdWaGMz UWcgUVhOcF lXNGdiVyBG eWEyVjBMan hpIGNqNDVM aUJKYmkgQX lNREV6TENC RyBkV3BwSU ZCb1lYIEp0 WVNCbGMzUm ggWW14cGMy aGxaQyBCaE lITjFZbk5w IFpHbGhjbm tnYVcgNGdT VzVrYjI1bC BjMmxoSUhS dklIIE4wY2 1WdVozUm8g Wlc0Z2FYUn pJSCBCeVpY TmxibU5sIE lHbHVJSFJv WlMgQnlaV2 RwYjI0dSBQ R0p5UGpFd0 xpIEJVYUdV Z1kyOXQgY0 dGdWVlS0Ft WCBNZ2JXRn BiaUIwIGFH VnlZWEJsZF ggUnBZeUJo Y21WaCBjeU JwYm1Oc2RX IFJsSUdSbG NtMWggZEc5 c2IyZDVMQy BCd1lXbHVJ RzFoIGJtRm 5aVzFsYm4g UXNJR05oY2 1ScCBiM1po YzJOMWJHIE Z5SUdScGMy VmggYzJWek xDQmhibSBR Z2NtVnpjR2 x5IFlYUnZj bmtnWkcgbH paV0Z6WlhN dQogICAgIC AgIDwvc3Bh bj4KICAgIC AgICAKICAg ICAgICA=
See Company Q&A
Fuji Pharma

πŸ“Š Get full analytics about Fuji Pharma

Sign up for free or log in

πŸ“– Get insights from "The Checklist Value Investor β€” A Smarter Way to Pick Stocks" now!

© 2024 - 2026 InsightfulValue.com. All rights reserved. Newsletter
Legal